# Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

> **NCT03312517** · PHASE4 · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 12 (actual)

## Conditions studied

- Insomnia

## Interventions

- **DRUG:** Suvorexant 10 mg
- **DRUG:** Suvorexant 20 mg
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03312517
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-15
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312517, "Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03312517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*